OncoMatch

OncoMatch/Clinical Trials/NCT07254585

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Is NCT07254585 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SYS6010 and Enlonstobart for head and neck squamous cell carcinoma.

Phase 2RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.NCT07254585Data as of Jun 2026Location: China

Treatment: SYS6010 · EnlonstobartThis study is a n open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

SYS6010Enlonstobart

Cancer type

Head and Neck Squamous Cell Carcinoma

Biomarker criteria

Required: PD-L1 (CD274) positive (CPS≥1) (CPS≥1)

baseline PD-L1 positivity (CPS≥1) must be confirmed by the central laboratory; for participants who have previously received systemic antitumor treatment, there is no restriction on baseline PD-L1 expression

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Lab requirements

Blood counts

Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention

Kidney function

Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention

Liver function

Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention

Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07254585 currently recruiting?

Yes, this trial is currently recruiting patients.

Does this trial require CD274?

Yes, CD274 positive (CPS≥1) is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify